Bernardo Cortese, Fesc

List of Publications by Year
in descending order

80 papers	2,275 citations	471509 17 h-index	223800 46 g-index
83 all docs	83 docs citations	83 times ranked	2924 citing authors

#	Article	IF	Citations
1	Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet, The, 2015, 385, 2465-2476.	13.7	1,043
2	Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment. Journal of Thoracic Disease, 2016, 8, E1150-E1162.	1.4	267
3	Paclitaxel coated balloons for coronary artery interventions: A comprehensive review of preclinical and clinical data. International Journal of Cardiology, 2012, 161, 4-12.	1.7	90
4	Radiation Exposure and Vascular AccessÂinÂAcute Coronary Syndromes. Journal of the American College of Cardiology, 2017, 69, 2530-2537.	2.8	61
5	Immediate and midterm outcomes following primary PCI with bioresorbable vascular scaffold implantation in patients with ST-segment myocardial infarction: insights from the multicentre â€œRegistro ABSORB Italianoâ€•(RAI registry). EuroIntervention, 2015, 11, 157-162.	3.2	46
6	Immediate and short-term performance of a novel sirolimus-coated balloon during complex percutaneous coronary interventions. The FAtebenefratelli SIrolimus COated-balloon (FASICO) registry. Cardiovascular Revascularization Medicine, 2017, 18, 487-491.	0.8	38
7	Clinical Comparison With Short-Term Follow-Up of Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Stent in Primary Percutaneous Coronary Interventions. American Journal of Cardiology, 2015, 116, 705-710.	1.6	36
8	Bioresorbable vascular scaffold implantation for the treatment of coronary in-stent restenosis: Results from a multicenter Italian experience. International Journal of Cardiology, 2015, 199, 366-372.	1.7	34
9	Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis. Circulation: Cardiovascular Interventions, 2016, 9, e003148.	3.9	33
10	Early results following everolimus-eluting bioresorbable vascular scaffold implantation for the treatment of in-stent restenosis. International Journal of Cardiology, 2014, 173, 513-514.	1.7	32
11	Clinical performance of a novel sirolimus-coated balloon in coronary artery disease: EASTBOURNE registry. Journal of Cardiovascular Medicine, 2021, 22, 94-100.	1.5	29
12	Treatment of bifurcation lesions with drug-coated balloons: A review of currently available scientific data. International Journal of Cardiology, 2016, 220, 589-594.	1.7	26
13	Sealing spontaneous coronary artery dissection with bioresorbable vascular scaffold implantation: Data from the prospective â€œRegistro Absorb Italianoâ€•(RAI Registry). International Journal of Cardiology, 2016, 212, 44-46.	1.7	26
14	Recurrent in-stent restenosis, certainty of its origin, uncertainty about treatment. International Journal of Cardiology, 2017, 230, 91-96.	1.7	26
15	Clinical, Angiographic, and Procedural Correlates of Acute, Subacute, and Late Absorb Scaffold Thrombosis. JACC: Cardiovascular Interventions, 2017, 10, 1809-1815.	2.9	26
16	<scp>Drugâ€Coated</scp> balloons vs drugâ€eluting stents for the treatment of small coronary artery disease: A metaâ€analysis of randomized trials. Catheterization and Cardiovascular Interventions, 2021, 98, 66-75.	1.7	23
17	A Prospective Evaluation of a Pre-Specified Absorb BVS Implantation Strategy in ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2017, 10, 1855-1864.	2.9	22
18	Optical coherence tomography, intravascular ultrasound or angiography guidance for distal left main coronary stenting. The <scp>ROCK</scp> cohort <scp>II</scp> study. Catheterization and Cardiovascular Interventions, 2022, 99, 664-673.	1.7	20

#	Article	IF	Citations
19	Randomized comparison of operator radiation exposure comparing transradial and transfemoral approach for percutaneous coronary procedures: rationale and design of the minimizing adverse haemorrhagic events by TRansradial access site and systemic implementation of angioX â€“ RAdiation Dose study (RAD-MATRIX). Cardiovascular Revascularization Medicine, 2014, 15, 209-213.	0.8	17
20	Angiographic performance of a novel sirolimus-coated balloon in native coronary lesions: the FAtebenefratelli SIrolimus COated NATIVES prospective registry. Journal of Cardiovascular Medicine, 2019, 20, 471-476.	1.5	17
21	Longâ€term followâ€up after sirolimusâ€coated balloon use for coronary artery disease. Final results of the NanolutÃ¨ study. Catheterization and Cardiovascular Interventions, 2020, 96, E496-E500.	1.7	17
22	A novel nanocarrier sirolimus-coated balloon for coronary interventions: 12-Month data from the NanolutÃ© Registry. Cardiovascular Revascularization Medicine, 2019, 20, 235-240.	0.8	16
23	Transradial versus transfemoral ancillary approach in complex structural, coronary, and peripheral interventions. Results from the multicenter ancillary registry: A study of the Italian Radial Club. Catheterization and Cardiovascular Interventions, 2018, 91, 97-102.	1.7	15
24	One-year clinical results of the Italian diffuse/multivessel disease ABSORB prospective registry (IT-DISAPPEARS). EuroIntervention, 2017, 13, 424-431.	3.2	15
25	Is vasospasm overestimated in acute coronary syndromes presenting with non-obstructive coronary artery disease? The case for intravascular imaging. International Journal of Cardiology, 2016, 203, 1125-1126.	1.7	14
26	Drug-coated balloons for coronary artery disease: current concepts and controversies. Future Cardiology, 2019, 15, 437-454.	1.2	14
27	Comparison Between Sirolimus- and Paclitaxel-Coated Balloon for Revascularization of Coronary Arteries: The SIRPAC (SIRolimus-PAClitaxel) Study. Cardiovascular Revascularization Medicine, 2021, 28, 1-6.	0.8	14
28	Registro Absorb Italiano (BVS-RAI): an investigators-owned and -directed, open, prospective registry of consecutive patients treated with the Absorbâ„¢ BVS: study design. Cardiovascular Revascularization Medicine, 2015, 16, 340-343.	0.8	12
29	Paclitaxel-coated balloon exerts late vessel healing and enlargement: A documented phenomenon with optical coherence tomography analysis. International Journal of Cardiology, 2016, 203, 551-552.	1.7	12
30	Bioresorbable vascular scaffolds for small vessels coronary disease: The BVSâ€save registry. Catheterization and Cardiovascular Interventions, 2016, 88, 380-387.	1.7	12
31	Biovascular scaffolding of distal left main trunk. International Journal of Cardiology, 2014, 177, 497-499.	1.7	11
32	Thirty-Day Outcomes After Unrestricted Implantation of Bioresorbable Vascular Scaffold (from the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.6	10
33	Coronary sinus perforation during reducer implantation. Catheterization and Cardiovascular Interventions, 2018, 91, 1291-1293.	1.7	10
34	Incidence of Adverse Events at 3 Months Versus at 12ÂMonths After Dual Antiplatelet Therapy Cessation in Patients Treated With Thin Stents With Unprotected Left Main or Coronary Bifurcations. American Journal of Cardiology, 2020, 125, 491-499.	1.6	10
35	Transradial approach for carotid artery stenting: A position paper from the Italian Society of Interventional Cardiology (SICIâ€GISE). Catheterization and Cardiovascular Interventions, 2021, 97, 1440-1451.	1.7	10
36	Very late bioresorbable vascular scaffold thrombosis due to late device recoil. International Journal of Cardiology, 2015, 189, 132-133.	1.7	9

#	Article	IF	Citations
37	A prospective evaluation of a standardized strategy for the use of a polymeric everolimusâ€eluting bioresorbable scaffold in STâ€segment elevation myocardial infarction: Rationale and design of the BVS STEMI STRATEGYâ€IT study. Catheterization and Cardiovascular Interventions, 2017, 89, 1129-1138.	1.7	9
38	Healing after coronary artery dissection: The effect of a drug coated balloon angioplasty in a bifurcation lesion. A lesson from intravascular ultrasound analysis. International Journal of Cardiology, 2016, 203, 298-300.	1.7	8
39	Bivalirudin or heparin in primary angioplasty performed through the transradial approach: results from a multicentre registry. European Heart Journal: Acute Cardiovascular Care, 2014, 3, 268-274.	1.0	7
40	Determinants of radiation dose during right transradial access: Insights from the RAD-MATRIX study. American Heart Journal, 2018, 196, 113-118.	2.7	7
41	Pregnancy and Spontaneous Coronary Artery Dissection: Lessons From Survivors and Nonsurvivors. Circulation, 2022, 146, 69-72.	1.6	7
42	First experience of drug-coated balloons for treatment of bioresorbable vascular scaffold restenosis. Cardiovascular Revascularization Medicine, 2017, 18, 482-486.	0.8	6
43	Clinical findings after bioresorbable vascular scaffold implantation in an unrestricted cohort of patients with ST-segment elevation myocardial infarction (from the RAI registry). International Journal of Cardiology, 2018, 258, 50-54.	1.7	6
44	Bioresorbable vascular scaffold versus everolimusâ€eluting stents or drug eluting balloon for the treatment of coronary inâ€stent restenosis: 1â€Year followâ€up of a propensity score matching comparison (the BIORESOLVEâ€ISR Study). Catheterization and Cardiovascular Interventions, 2018, 92, 668-677.	1.7	6
45	Absorb bioresorbable vascular scaffold vs. everolimusâ€eluting metallic stent in small vessel disease: A propensity matched analysis of COMPARE II, RAI, and MAASSTADâ€ABSORB studies. Catheterization and Cardiovascular Interventions, 2018, 92, E115-E124.	1.7	6
46	Clinical outcomes of overlapping versus nonâ€overlapping everolimusâ€eluting absorb bioresorbable vascular scaffolds: An analysis from the multicentre prospective RAI registry (ClinicalTrials.gov) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 377	1.7	6
47	Mortality Increase and Paclitaxel-Coated Device Use. JACC: Cardiovascular Interventions, 2019, 12, 2538-2540.	2.9	6
48	One-Year Results Following a Pre-Specified ABSORB Implantation Strategy in ST-Elevation Myocardial Infarction (BVS STEMI STRATEGY-IT Study). Cardiovascular Revascularization Medicine, 2019, 20, 700-704.	0.8	6
49	The hypothesis of an increased mortality following paclitaxel coated device use in peripheral vascular interventions (and the emerging era of metaâ€analysis based evidence). Catheterization and Cardiovascular Interventions, 2020, 95, 329-331.	1.7	6
50	Late Structural Discontinuity as a Possible Cause of Very Late Everolimus-Eluting Bioresorbable Scaffold Thrombosis. JACC: Cardiovascular Interventions, 2015, 8, e171-e172.	2.9	5
51	Clinical performance of a dedicated self-apposing stent for the treatment of left main stem disease. Results of the left Main AngioplasTy wIth a Self-apposing StEnt - the MATISSE study. Cardiovascular Revascularization Medicine, 2018, 19, 831-836.	0.8	5
52	One-year clinical outcomes after unrestricted implantation of the Absorb bioresorbable scaffold (RAI) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	3.2	5
53	Dual antiplatelet therapy strategies and clinical outcomes in patients treated with polymer-free biolimus A9-coated stents. EuroIntervention, 2020, 15, e1358-e1365.	3.2	5
54	Left main coronary artery and ostial left anterior descending coronary artery stenting in a single coronary artery during NSTEMI. The OCT response. International Journal of Cardiology, 2015, 184, 499-501.	1.7	4

#	Article	IF	Citations
55	Clinical and angiographic outcome of a single center, real world population treated with a dedicated technique of implantation for bioresorbable vascular scaffolds. The FAtebenefratelli Bioresorbable Vascular Scaffold (FABS) registry. Journal of Interventional Cardiology, 2017, 30, 427-432.	1.2	4
56	Drugâ€coated balloons for the treatment of inâ€stent restenosis in diabetic patients: A review of currently available scientific data. Catheterization and Cardiovascular Interventions, 2018, 92, E20-E27.	1.7	4
57	â€œFull-plastic jacketâ€•with everolimus-eluting Absorb bioresorbable vascular scaffolds: Clinical outcomes in the multicenter prospective RAI registry (ClinicalTrials.gov Identifier: NCT02298413). International Journal of Cardiology, 2018, 266, 67-74.	1.7	4
58	Prospective evaluation of drug eluting selfâ€apposing stent for the treatment of unprotected left main coronary artery disease: 1â€year results of the TRUNC study. Catheterization and Cardiovascular Interventions, 2020, 96, E142-E148.	1.7	4
59	Long-term efficacy of drug-coated balloon for renal artery in-stent restenosis. Egyptian Heart Journal, 2018, 70, 55-56.	1.2	3
60	Two-year clinical outcomes of the â€œItalian diffuse/multivessel disease absorb prospective registryâ€• (IT-DISAPPEARS). International Journal of Cardiology, 2019, 290, 21-26.	1.7	3
61	Safety and efficacy of polymerâ€free biolimusâ€eluting stents versus ultrathin stents in unprotected left main or coronary bifurcation: A propensity score analysis from the RAIN and CHANCE registries. Catheterization and Cardiovascular Interventions, 2020, 95, 522-529.	1.7	3
62	Small Vessel Coronary Artery Disease: Rationale for Standardized Definition and Critical Appraisal of the Literature. , 2022, 1, 100403.		3
63	TCT-425 Bioresorbable vascular scaffold technology for small vessel coronary artery disease: results from the Italian multicenter RAI Registry. Journal of the American College of Cardiology, 2016, 68, B171-B172.	2.8	2
64	Fracture with the newer bioresorbable vascular scaffolds. Catheterization and Cardiovascular Interventions, 2017, 90, 582-583.	1.7	2
65	Drug-coated balloons: room for development of BASKET-SMALL 2. Lancet, The, 2019, 393, 1933-1934.	13.7	2
66	Letter regarding the article â€œTransradial access compared with femoral puncture closure devices in percutaneous coronary proceduresâ€• An underestimated revolution. International Journal of Cardiology, 2010, 145, 383.	1.7	1
67	Biovascular scaffolds and reversible coronary aneurysm. International Journal of Cardiology, 2016, 214, 225-227.	1.7	1
68	Acutely malapposed bioresorbable vascular scaffold during primary angioplasty for spontaneous coronary artery dissection: Is a no-metal strategy better?. International Journal of Cardiology, 2016, 224, 335-336.	1.7	1
69	Occurrence and management of bioresorbable vascular scaffold failure in real-life studies. Journal of Thoracic Disease, 2017, 9, S935-S939.	1.4	1
70	Left Main restenosis in the DES era â€” a call for action. Cardiovascular Revascularization Medicine, 2018, 19, 466-470.	0.8	1
71	Oneâ€year clinical performance of ABSORB bioresorbable vascular scaffold in patients presenting with acute coronary syndromes: Results from the RAI registry. Catheterization and Cardiovascular Interventions, 2019, 93, 404-410.	1.7	1
72	Realâ€world reasons and outcomes for 1â€month versus longer dual antiplatelet therapy strategies with a polymerâ€free BIOLIMUS A9â€coated stent. Catheterization and Cardiovascular Interventions, 2020, 96, E248-E256.	1.7	1

#	Article	IF	Citations
73	RENASCENT III: First in Human Evaluation of the Novel Thin Strut MAGNITUDE Sirolimus-Eluting Ultra-High Molecular Weight MAGNITUDE Bioresorbable Scaffold: 9-Month Imaging and 2-Year Clinical Results. Circulation: Cardiovascular Interventions, 2021, 14, e010013.	3.9	1
74	Three-year results of ST-segment elevation myocardial infarction patients treated with a prespecified bioresorbable vascular scaffold implantation strategy: bVS STEMI STRATEGY-IT long-term. Journal of Cardiovascular Medicine, 2022, 23, 278-280.	1.5	1
75	Rationale and design of the randomized, multicenter EREMUS trial, a study that investigates how to achieve low restenosis and early reendothelialization after percutaneous coronary interventions. Catheterization and Cardiovascular Interventions, 2011, 78, 32-37.	1.7	0
76	Coronary dissection at site of recent BRS deployment. International Journal of Cardiology, 2014, 174, e90-e92.	1.7	0
77	Drug-Eluting Balloon In-Stent Restenosis Treatment: Why not?. Heart Lung and Circulation, 2017, 26, e102-e103.	0.4	0
78	How is the cardiovascular patient managed during Covidâ€19 pandemic? A report from the frontline. Catheterization and Cardiovascular Interventions, 2020, 96, E565.	1.7	0
79	299â€ƒ3-Year results of STEMI patients treated with a pre-specified BVS implantation strategy: BVS SYTEMI strategy-it long term. European Heart Journal Supplements, 2021, 23, .	0.1	0
80	Drug-Coated Balloons for Unselected Real World Patients: Are We There Yet?. Korean Circulation Journal, 0, 52, .	1.9	0